The Theranos investigation is likely in the deliberative stage, determining what corrective action might be taken for a company that operated on the edge. In this environment a sacrifice might have occurred as the chief operating officer and one of the original architects of the company’s system leaves the firm. One of the primary Theranos executives targeted by regulators with a potential ban from the medical testing industry, COO Ramesh (Sunny) Balwani, is departing the blood testing firm. The company is under both regulatory and criminal investigations related to its pin-prick blood testing methodology and the generally secretive methods that…
Theranos Investigation Continues As COO Out At Firm
Mark Melin
Mark Melin is an alternative investment practitioner whose specialty is recognizing the impact of beta market environment on a technical trading strategy. A portfolio and industry consultant, wrote or edited three books including High Performance Managed Futures (Wiley 2010) and The Chicago Board of Trade’s Handbook of Futures and Options (McGraw-Hill 2008) and taught a course at Northwestern University's executive education program.